Detalhe da pesquisa
1.
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
Future Oncol
; 18(9): 1039-1054, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34918545
2.
Novel molecular targets for the treatment of lung cancer.
Curr Opin Oncol
; 32(1): 37-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31599770
3.
Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Curr Oncol Rep
; 22(5): 52, 2020 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32363551
4.
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Cell Commun Signal
; 17(1): 137, 2019 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31660987
5.
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Curr Oncol Rep
; 20(9): 70, 2018 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30030656
6.
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Br J Cancer
; 116(6): 802-810, 2017 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28170370
7.
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Clin Chem
; 63(3): 751-760, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28073897
8.
Relationship between gene mutation and lung cancer metastasis.
Cancer Metastasis Rev
; 34(2): 243-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25937072
9.
Genetics and biomarkers in personalisation of lung cancer treatment.
Lancet
; 382(9893): 720-31, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23972815
10.
Avelumab in non-small-cell lung cancer.
Lancet Oncol
; 19(11): 1423-1424, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262188
11.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Lancet Oncol
; 19(3): e126, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29508751
12.
BRAFV600E and BRAF-inactivating mutations in NSCLC.
Lancet Oncol
; 18(10): 1286-1287, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919012
13.
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Mol Cancer Ther
; 22(7): 833-843, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999986
14.
Overcoming MET-mediated resistance in oncogene-driven NSCLC.
iScience
; 26(7): 107006, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534190
15.
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
JTO Clin Res Rep
; 4(8): 100533, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649681
16.
Large-scale screening for somatic mutations in lung cancer.
Lancet
; 387(10026): 1354-1356, 2016 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777918
17.
Trends in immunotherapy for brain metastases.
Lancet Oncol
; 17(7): 859-860, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27267610
18.
RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
Lancet Oncol
; 17(12): 1623-1625, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825637
19.
Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.
Cancers (Basel)
; 14(6)2022 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326725
20.
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
J Clin Invest
; 132(13)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579943